WJ35435
Product Specifications
UNSPSC Description
WJ35435 is a dual-targeted anticancer hybrid that induces anti-HDAC (in particular HDAC1 and HDAC6) and anti-topoisomerase I activities that causes DNA damage associated with a low DNA repair capability and induces cell cycle arrest at G1- and G2-phase to apoptosis. WJ35435 induces histone H3 acetylation and phosphorylation, α-tubulin acetylation and γ-H2AX formation to achieve anti-HDAC effect. WJ35435 is promising for research of cancer[1].
Target Antigen
Apoptosis; HDAC; Topoisomerase
Type
Reference compound
Related Pathways
Apoptosis;Cell Cycle/DNA Damage;Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/wj35435.html
Smiles
O=C(C1=CC=CC2=CC3=C(N=C21)C=CC=C3)NCCCCCC(NO)=O
Molecular Weight
351.40
References & Citations
[1]Yu C C, et al. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I[J]. Biochemical pharmacology, 2014, 90(3): 320-330.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-117688/WJ35435-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-117688/
Clinical Information
No Development Reported
CAS Number
1620054-84-3
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6279176-01 0.2 mL
BTF3L4, CT (BTF3L4, Transcription factor BTF3 homolog 4, Basic transcription factor 3-like 4) (AP)
Ask
View Details 
MBS6279176-02 5x 0.2 mL
BTF3L4, CT (BTF3L4, Transcription factor BTF3 homolog 4, Basic transcription factor 3-like 4) (AP)
Ask
View Details